NVS
AI meets the pill factory
Novartis CEO Vas Narasimhan is joining Anthropic’s board, which is a pretty loud way of saying the pharma giant wants AI in the room where it happens — specifically, the expensive, slow, very-not-fun process of discovering drugs.
Why this matters
Drug development is basically a giant game of "find the one useful molecule hiding in a haystack the size of Wyoming." If AI can help narrow that haystack, Novartis could get to better medicine faster, cut some trial-and-error waste, and sharpen its competitive edge.
Not just a vanity seat
This isn’t just a trophy-chair moment for Narasimhan. It signals Novartis is trying to embed AI more deeply into its operations, while Anthropic gets a high-profile path into a regulated, high-value industry where its Claude models can prove they’re more than just clever text generators.
Big picture
The AI drug-discovery pitch has been around for years, but moves like this show the industry is still moving from hype to actual operating strategy. If Novartis can turn AI into a real productivity tool, that’s the kind of boring-sounding advantage investors usually love most.